In certain embodiments, any controlled-release otic formulation described herein increases the exposure of an active agent and increases the length of time that the concentration of the active agent is above C min by about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90% compared to a formulation that is not a controlled-release otic formulation
Clinical Microbiology Reviews , 15 (2), 194-222
BPC-157 : TB500 (Thymosin Beta 4) : BPC-157 & TB500 (Thymosin Beta 4) CERTIFICATES OF ANALYSIS 6 COAs BN-26BT11-001 Current Variant: Size: 10mg-10mg BPC-157 11.7 mg / 11.85 mg TB-500 11.54 mg / 11.44 mg BN-25BT55-004 Current Variant: Size: 5mg-5mg BPC-157 5.89 mg / 5.73 mg TB-500 5.68 mg / 5.57 mg BN-24BT55 Upcoming Variant: Size: 5mg-5mg BPC-157 5.57 mg TB-500 5.49 mg BN-25BT11-002 Previous Variant: Size: 10mg-10mg BN-25BT11-001 Previous Variant: Size: 10mg-10mg BN-24BT55-001 Previous Variant: 5 mg / 5 mg Formulation BPC-157 and TB-500 (Thymosin Beta-4) are research peptides supplied for use in controlled laboratory and analytical environments
Dietary plant polysaccharides for cancer prevention: role of immune cells and gut microbiota, challenges and perspectives
Prevention of Bacterial Growth: Storing peptides in a refrigerator reduces the risk of bacterial contamination, which can occur at higher temperatures
